Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 9/20 | 0.44 |
| ▸ | KDR | P35968 | 8/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 5/20 | 0.43 |
| ▸ | FLT3 | P36888 | 5/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987567 | 1.00 | PDGFRB (0.44) | PDGFRBKDRFGFR1TLK2KIT | |
| SCHEMBL4992432 | 0.93 | PDGFRB (0.51) | PDGFRBKDRFGFR1TLK2KIT | |
| SCHEMBL4992434 | 0.93 | PDGFRB (0.51) | PDGFRBKDRFGFR1TLK2KIT | |
| SCHEMBL4988151 | 0.91 | PDGFRB (0.46) | PDGFRBKDRFGFR1KITFLT3 | |
| SCHEMBL4988142 | 0.91 | PDGFRB (0.46) | PDGFRBKDRFGFR1KITFLT3 | |
| SCHEMBL4998826 | 0.91 | PDGFRB (0.41) | PDGFRBKDRFGFR1TLK2KIT | |
| SCHEMBL4998828 | 0.91 | PDGFRB (0.41) | PDGFRBKDRFGFR1TLK2KIT | |
| SCHEMBL4995411 | 0.89 | FLT3 (0.41) | PDGFRBKDRFGFR1TLK2KIT | |
| SCHEMBL4995416 | 0.89 | FLT3 (0.41) | PDGFRBKDRFGFR1TLK2KIT | |
| SCHEMBL4984583 | 0.86 | PDGFRB (0.45) | PDGFRBKDRFGFR1KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060194863-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-08-31 | — | — | US | disclosed |
| US-7098236-B2 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-7015220-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20050228036-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2005-10-13 | — | — | US | disclosed |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ANDREWS STEVEN W (US) | 2004-10-07 | — | — | US | disclosed |
| US-6765012-B2 | FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | ALLERGAN, INC. | 2004-07-20 | — | — | US | disclosed |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228036-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | PDGFRB 307/4885KDR 256/4885FGFR1 346/4885 |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | PDGFRB 307/4885KDR 256/4885FGFR1 346/4885 |
| US-20060194863-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | PDGFRB 307/4885KDR 256/4885FGFR1 346/4885 |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | PDGFRB 307/4885KDR 256/4885FGFR1 346/4885 |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | PDGFRB 307/4885KDR 256/4885FGFR1 346/4885 |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | PDGFRB 307/4885KDR 256/4885FGFR1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.